Velcade is indicated for the treatment of patients with Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
1. Approved Labelling
Velcade is indicated for the treatment of patients with Mantle Cell Lymphoma.
2. Treatment Regimen
The recommended starting dose of Velcade is 1.3 mg/m2. Velcade may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL.
Velcade (1.3 mg/m2) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (VcR-CAP) for six 3-week treatment cycles. VELCADE is administered first followed by rituximab. Velcade is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period on Days 12-21.
For patients with a response first documented at cycle 6, two additional VcR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of Velcade.
Please see section 5 of the PI
All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.